Our News

Pharmazac launched the new product  Vasitimb / ezetimibe + simvastatin for theprevention of cardiovascular events, for hypercholesterlaemia and for theHomozygous Familial Hypercholesterolaemia. Therapeutic Indications Prevention of Cardiovascular Events Vasitimb is […]

Pharmazac launched the new product Abelfiz / aripiprazole 10, 15 and 30mg in hard tablets  for the treatment of schizophrenia in adults and in adolescents aged […]

Pharmazac participates in CPhI 2018.

Pharmazac has developed in its laboratories and launched in the Greek pharmaceutical market a nutraceutical, the titrate extract of Petasitis Hybridus in liquid hard gelatin capsules […]

Pharmazac launched the new product Quental/quetiapine 50,200,300 and 400mg in prolonged release tablets for the treatment of schizophrenia and bipolar disorders.

  Pharmazac a Member of the Hellenic Association of Pharmaceutical Companies,  announces the completion of the successful Conference of the Hellenic Society of Headache,  that took place  […]

Pharmazac launched the first Rosuvastatin generic in the Greek Pharmaceutical Market. Rosuvastatin is available in two forms of 14 and 30 film coated tablets and composition of […]

Pharmazac has released the new product Nitastin 20mg film coated tablet for treatment of heart disease In addition to the hypolipidemic actions Nitastin has beneficial effects […]

Pharmazac has released the new product Ractilen (rasagiline tabs 1mg/tab ) for the treatment of PD

Pharmazac has released the new product Calcium Folinate,  an injectable solution 200mg/20ml Bt x 1 vial x20ml for intravenous or intramuscular use. Calcium Folinate / Pharmazac is the only available generic product in the Greek market.

PharmaZac sponsors the medical book “The Neuropsychology of Epilepsy” of Dr. P. Patrikelis Neuropsychologist Ph.D University of Ioannina Medical School and Dr. S. Gatzonis, Neurologist Dep. […]